1.	PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Closed Age: 20 and over Sponsor: Other Protocol IDs: 9461700718, NCT00173524
2.	Iressa Case Control Study in Japan Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: D791AL00002, V-15-33, OZV1533, NCT00252759
3.	Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913C00046, NCT00536107
4.	SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Phase: Phase IV Type: Treatment Status: Completed Age: 19 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: D7913L00067, NCT00608868
5.	Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913L00071, NCT00770588
6.	A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Phase: Phase IV Type: Biomarker/Laboratory analysis, Natural history/Epidemiology Status: Completed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0052 SubStudy, NCT01000740
7.	Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791AC00014, NCT01203917
8.	A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 to5 Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0143, NCT00234429
9.	Iressa v BSC (Best Supportive Care) in First Line NSCLC Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0711, D7913C00711, NCT00259064
10.	Phase III Randomized Study of ZD 1839 Combined With Gemcitabine and Cisplatin in Chemotherapy Naive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer (Summary Last Modified 07/2001) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ZENECA-1839IL/0014, NCT00006048
11.	Phase III Randomized Study of ZD 1839 Combined With Paclitaxel and Carboplatin in Chemotherapy Naive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer (Summary Last Modified 07/2001) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ZENECA-1839IL/0017, MSKCC-00100, NCT00006049
12.	Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TLK286.3020, NCT00080340
13.	Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000377545, U10CA021115, ECOG-E1302, E1302, NCT00088907
14.	Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI UNKPRI 12, IRUSIRES0215, CPTAIV-0020-417, B9E-US-X423, NCT00193596
15.	Iressa 2nd Line Phase III Study in Japan Phase: Phase III Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791AL00001, V-15-32, NCT00252707
16.	First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791AC00007, Iressa Pan Asian Study (IPASS), NCT00322452
17.	Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
18.	Iressa Follow-up Trial Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0555, D7913L00008, NCT00357734
19.	First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Phase: Phase III Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: NCCCTS-05-126, D7913L00054, NCT00455936
20.	Randomized Gefitinib Trial Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: ONC-2008-001, NCT00807066
21.	Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0704, EudraCT no.2004-002662-38, NCT00206219
22.	S0023: Combination Chemo Plus RT With or Without Gefitinib in Treating Patients With Unresectable Stage III NSCLC Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000068706, SWOG-S0023, CAN-NCIC-BR15, NCCTG-S0023, S0023, BR15, NCT00020709
23.	Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: BR19, CAN-NCIC-BR19, ECOG-CAN-NCIC-BR19, SWOG-CAN-NCIC-BR19, CDR0000258118, NCIC-BR.19, NCT00049543
24.	BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: BL11, CAN-NCIC-BL11, CDR0000486873, NCT00352079
25.	A Study of Alimta/Cisplatin/Gefitnib for Asian Non-smoking Patients With Non Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13021, H3E-CR-S131, NCT01017874